Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shot for lupus enters early human testing

NCT ID NCT06625671

First seen Dec 29, 2025 · Last updated Jun 19, 2026 · Updated 27 times

Summary

This study tests a new injection, DB-2304, for safety and how the body handles it. It includes healthy volunteers and people with lupus (SLE or CLE). The goal is to check for side effects and see how the drug works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Site AUS01-0

    COMPLETED

    Melbourne, Victoria, 3004, Australia

  • US02-0

    RECRUITING

    San Antonio, Texas, 78215, United States

  • US03-0

    RECRUITING

    Clearwater, Florida, 33765, United States

  • US04-0

    RECRUITING

    Irving, Texas, 75061, United States

  • US05-0

    RECRUITING

    Orlando, Florida, 32808, United States

  • US06-0

    RECRUITING

    La Palma, California, 90623, United States

  • US08-0

    NOT_YET_RECRUITING

    Syracuse, New York, 13210, United States

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.